Regenxbio Q3 operating expenses USD 44.696 million
RGNX•Regenxbio reported third-quarter operating expenses of USD 44.696 million, license and royalty revenue of USD 5.244 million, and a net loss of USD 40.738 million.
1. Quarterly results
Regenxbio reported third-quarter operating expenses of USD 44.696 million, license and royalty revenue of USD 5.244 million, and a net loss of USD 40.738 million.
